Business context and reporting period
Teladoc Health, Inc. filed this unaudited Form 10-Q for the three months ended March 31, 2024. The company operates two reportable segments: Teladoc Health Integrated Care, which provides virtual medical and chronic-care services, and BetterHelp, which provides virtual therapy and wellness services.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 or prior period |
|---|---|---|
| Revenue | $646.1 million | $629.2 million; up 3% |
| Operating loss | $87.1 million | $77.1 million |
| Net loss | $81.9 million; $0.49 per diluted share | $69.2 million; $0.42 per diluted share |
| Adjusted EBITDA (non-GAAP) | $63.1 million | $52.8 million |
| Operating cash flow | $8.9 million | $13.2 million |
| Free cash flow (non-GAAP) | $(26.6) million | $(32.5) million |
| Cash and cash equivalents | $1,097.9 million | $1,123.7 million at December 31, 2023 |
Cost of revenue was $194.5 million, about 30% of revenue, versus $190.1 million, also about 30%. Operating expenses included $183.3 million of advertising and marketing and $95.1 million of intangible amortization. The amortization increase was a significant contributor to the higher operating loss. Cash used in investing activities was $35.5 million, primarily for capitalized software development; financing activities provided $1.8 million.
Convertible senior notes had a net carrying amount of $1,539.5 million. This included $1.0 billion of 1.25% notes due 2027 and $550.0 million of Livongo notes due June 2025; only $0.7 million remained outstanding on the other 2025 notes. The company reported compliance with all debt covenants. Current liabilities were $388.8 million and total stockholders’ equity was $2,288.9 million at quarter-end.
Material changes versus the prior comparable period
- Integrated Care revenue rose 8% to $377.1 million, while segment Adjusted EBITDA increased 36% to $47.7 million; its margin improved to 12.6% from 10.0%.
- BetterHelp revenue fell 4% to $269.0 million, and segment Adjusted EBITDA fell 12% to $15.5 million; its margin declined to 5.7% from 6.3%. Average monthly paying users decreased 11% to 0.42 million.
- Overall revenue growth reflected higher visit revenue and international revenue, which rose 13% to $98.5 million. U.S. revenue rose 1% to $547.6 million.
- Intangible amortization increased 42% to $95.1 million, including $18.6 million of additional expense from accelerated Livongo trademark amortization, reducing earnings by $0.11 per share.
- Net loss widened by $12.7 million. Adjusted EBITDA increased 20%, but operating cash flow decreased, largely due to higher incentive compensation payments.
Outlook, risks, contingencies, and unusual items
- No quantified revenue or earnings guidance is provided in the supplied filing text. Management expects positive operating cash flow to increase in 2024 and believes existing cash is sufficient for working capital, capital expenditures, and contractual obligations for at least 12 months.
- The company recorded $9.7 million of restructuring costs in Q1 and previously estimated total 2024 pretax restructuring charges of $12 million to $16 million.
- The CEO departed effective April 5, 2024. The company expects approximately $6.4 million of related costs in Q2 2024, including $1.2 million of salary continuation and bonus and $5.2 million of stock-based compensation.
- Management identifies seasonality, customer retention and utilization, BetterHelp user trends, and competition and market acceptance among factors affecting performance. A 1% interest-rate change would affect interest income by approximately $11 million over the next 12 months.
- Legal matters include an appeal in a securities class action, stayed shareholder derivative litigation, putative BetterHelp privacy-related class actions, and a patent infringement suit. Management says it intends to defend these matters and does not expect litigation to have a material adverse impact; outcomes remain uncertain.
- The company notes that goodwill impairment could arise if BetterHelp forecasts or margins weaken, or if its share price declines significantly. It reported no material changes to the risk factors in its 2023 Form 10-K.
Important facts for investors to verify
- Whether Integrated Care growth and margin gains can offset continued weakness in BetterHelp revenue and paying users.
- Progress toward management’s 2024 operating-cash-flow expectation, considering Q1 cash generation and negative free cash flow.
- The timing and funding implications of the $550 million Livongo notes due in June 2025 and the other remaining 2025 notes.
- The full-year effect of accelerated Livongo trademark amortization, restructuring charges, and CEO separation costs.
- Developments in the disclosed legal proceedings and any resulting financial exposure.
- Potential dilution: common shares outstanding were 169.3 million at March 31, 2024, and the company reserved 8.7 million shares for conversion of its notes.